Warning on H1N1 metatags
This article was originally published in The Tan Sheet
Executive Summary
FDA warns My Cosmetic Co. to stop using H1N1 flu virus-related metatags to drive consumers to its Web site for the Zeolite Internal Detox 250-mg supplement product because they make the an unapproved product for the mitigation, prevention and treatment of the H1N1 flu virus. The agency acknowledges in the Dec. 1 warning letter that the Australian firm removed problematic claims that Zeolite could "remove the toxins of Swine Flu," "protect against the swine flu" and "induce a significant inhibitory effect upon viral proliferation," but the remaining metatags remain a problem. Like FDA, industry trade groups both warn that promoting supplements as cures or treatments for H1N1 is illegal (1"The Tan Sheet" Dec. 14, 2009, In Brief)
You may also be interested in...
Industry targets bogus H1N1 claims
Dietary supplement industry trade groups offer enforcement help against fraudulent H1N1 flu virus claims with their second joint statement this year noting that federal regulations do not allow supplements to make disease claims. The associations note Dec. 7 that FDA and the Federal Trade Commission issued 147 warning letters since May on products making H1N1 prevention or cure claims. "FTC informed us that they were not getting the results they wanted," American Herbal Product Association President Michael McGuffin said in a Dec. 10 e-mail. Natural Products Association Executive Director John Gay said that since the groups' May statement, the cold and flu season started and flu-related claims are more prevalent. The Natural Products Foundation's Truth in Advertising program in October referred 10 firms to FDA and FTC after they failed to amend their ads to comply with regulations (1"The Tan Sheet" Oct. 29, 2009, In Brief). FDA says the bogus H1N1 claims it is finding have slowed since May from seven to 10 a day to as many in a week (2"The Tan Sheet" Oct. 19, 2009). "We are continuing with the same enforcement effort that we have used," a spokesman said. The Consumer Healthcare Products Association, the Council for Responsible Nutrition and the United Natural Products Alliance also signed the joint industry statement
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.